Copyright
©The Author(s) 2021.
World J Virol. Mar 25, 2021; 10(2): 34-52
Published online Mar 25, 2021. doi: 10.5501/wjv.v10.i2.34
Published online Mar 25, 2021. doi: 10.5501/wjv.v10.i2.34
Table 1 Principles of coronavirus disease 2019 management according to disease severity and presence of comorbidities
| Severity | No comorbidities present | Comorbidities present |
| Mild | Conservative at home | Steroids,or/and plasma therapy |
| Moderate | Conservative at home | Steroids, or/and plasma therapy |
| Severe | Hospitalized: Treatment focused on the complication | Intravenous fluid, oxygen, corticosteroids |
- Citation: Dominari A, Hathaway III D, Kapasi A, Paul T, Makkar SS, Castaneda V, Gara S, Singh BM, Agadi K, Butt M, Retnakumar V, Chittajallu S, Taugir R, Sana MK, KC M, Razzack S, Moallem N, Alvarez A, Talalaev M. Bottom-up analysis of emergent properties of N-acetylcysteine as an adjuvant therapy for COVID-19. World J Virol 2021; 10(2): 34-52
- URL: https://www.wjgnet.com/2220-3249/full/v10/i2/34.htm
- DOI: https://dx.doi.org/10.5501/wjv.v10.i2.34